Li-Fraumeni syndrome (LFS) is one of the most penetrant forms of familial cancer susceptibility syndromes, characterized by an early age of tumor onset and a wide spectrum of malignant tumors. Patients with TP53 mutations are predisposed to develop sarcomas, early-onset breast cancer, brain tumors, leukemia, and adrenocortical carcinomas.1,2 The lifetime risk of cancer in these patients is extraordinarily high with 50% of patients having a diagnosis of cancer by the age of 30 and 90% by the age of 50.3 Identifying LFS in patients with cancer is clinically imperative because these patients have an increased sensitivity to ionizing radiation and are more likely to develop radiation-induced secondary malignancies.4–7 This case report describes a young woman whose initial presentation of LFS was early-onset breast cancer and whose subsequent treatment with breast conservation likely resulted in the rapid development of a secondary malignancy arising in her radiation field.
OlivierMGoldgarDESodhaN. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res2003;63:6643–6650.
GonzalezKDNoltnerKABuzinCH. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol2009;27:1250–1256.
LustbaderEDWilliamsWRBondyML. Segregation analysis of cancer in families of childhood soft tissue sarcoma patients. Am J Hum Genet1992;51:344–356.
LimacherJMFrebourgTNatarajan-AmeSBergeratJP. Two metachronous tumours in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer2001;96:238–242.
CohenRJCurtisREInskipPDFraumeniJFJr. The risk of developing second cancers among survivors of childhood soft tissue sarcoma. Cancer2005;103:2391–2396.
KonySJde VathaireFChrompretA. Radiation and genetic factors in the risk of second malignant neoplasm’s after a first cancer in childhood. Lancet1997;350:91–95.
HeymannSDelalogeSRahalA. Radio-induced malignancies after breast cancer post operative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol2010;5:104–109.
GreenburgCCLipsitzSRHughsME. Institutional variation in the surgical treatment of breast cancer: a study of the NCCN. Ann Surg2011;254:339–345.
LimacherJMFrebourgTNatarajan-AmeSBergeratJP. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer2001;96:238–242.
RubinoCde VathaireFShamsaldinA. Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer2003;895:840–846.
DalyMBAxilbundJEBuysS. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 12012. Available at NCCN.org. Accessed June 18 2012.
MalkinDSmythKShumanC. Establishment of a dedicated cancer genetics program in a tertiary pediatric center [abstract]. Am J Hum Genet1999;65:Abstract 386.
MasciariSDillonDDickMG. Breast cancer phenotype in women with TP53 germ-line mutations: an LFS consortium effort [abstract]. J Clin Oncol2011;29(Suppl):Abstract 1519.
WilsonJRBatemanACHansonsH. A novel Her2 positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet2010;47:771–774.
Melhem-BertrandtABojadzievaJReadyKJ. Early onset Her2-positive breast cancer is associated with germline TP53 mutations. Cancer2012;118:908–913.